ME02805B - Inhibitori cdc7 - Google Patents
Inhibitori cdc7Info
- Publication number
- ME02805B ME02805B MEP-2017-173A MEP2017173A ME02805B ME 02805 B ME02805 B ME 02805B ME P2017173 A MEP2017173 A ME P2017173A ME 02805 B ME02805 B ME 02805B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- cancer
- fluoropyrimidin
- isoindolin
- pyrazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Claims (13)
1. Spoj, naznačen time što je 3-(5-fluorpirimidin-4-il)-3-metil-6-(1H-pirazol-4-il)izoindolin-1-on, ili farmaceutski prihvatljiva sol ili njegov hidrat.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 3-(5-fluorpirimidin-4-il)-3-metil-6-(1H-pirazol-4-il)izoindolin-1-on.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je R enantiomer 3-(5-fluorpirimidin-4-il)-3-metil-6-(1H-pirazol-4-il)izoindolin-1-ona, ili njegova farmaceutski prihvatljiva sol.
4. Spoj u skladu s patentnim zahtjevom 3, naznačen time što je R enantiomer 3-(5-fluorpirimidin-4-il)-3-metil-6-(1H-pirazol-4-il)izoindolin-1-ona.
5. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je S enantiomer 3-(5-fluorpirimidin-4-il)-3-metil-6-(1H-pirazol-4-il)izoindolin-1-ona, ili njegova farmaceutski prihvatljiva sol.
6. Spoj u skladu s patentnim zahtjevom 5, naznačen time što je S enantiomer 3-(5-fluorpirimidin-4-il)-3-metil-6-(1H-pirazol-4-il)izoindolin-1-ona.
7. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 3-(5-fluorpirimidin-4-il)-3-metil-6-(1H-pirazol-4-il)izoindolin-1-on, ili njegov hidrat.
8. Spoj u skladu s patentnim zahtjevom 7, koji je hidrat u kristalnom obliku naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu s karakterističnim signalima, u 2θ ± 0,2, na 22,27 i jednim ili više od 13,46, 16,54, 16,66, 18,10 i 23,13.
9. Farmaceutski pripravak, naznačen time što sadrži spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-8, kao i farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
10. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačeni time što su namijenjeni upotrebi u terapiji.
11. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačeni time što su namijenjeni upotrebi u liječenju raka.
12. Spoj ili sol namijenjeni upotrebi u skladu s patentnim zahtjevom 11, naznačeni time što se rak bira iz skupine koju čine rak dojke, trostruko negativni rak dojke, rak jajnika, rak pluća, kolorektalni rak, hematološki rak, te leukemija.
13. Spoj ili sol namijenjeni upotrebi u skladu s patentnim zahtjevom 12, naznačeni time što je rak kolorektalni rak.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782798P | 2013-03-14 | 2013-03-14 | |
| US201361789108P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/021466 WO2014143601A1 (en) | 2013-03-14 | 2014-03-07 | CDC7 Inhibitors |
| EP14712966.2A EP2970221B1 (en) | 2013-03-14 | 2014-03-07 | Cdc7 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02805B true ME02805B (me) | 2018-01-20 |
Family
ID=50382704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-173A ME02805B (me) | 2013-03-14 | 2014-03-07 | Inhibitori cdc7 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9156824B2 (me) |
| EP (1) | EP2970221B1 (me) |
| JP (1) | JP6064079B2 (me) |
| KR (1) | KR101718645B1 (me) |
| CN (1) | CN105008351B (me) |
| AP (1) | AP2015008734A0 (me) |
| AU (1) | AU2014228374B2 (me) |
| BR (1) | BR112015020466B1 (me) |
| CA (1) | CA2900773C (me) |
| CL (1) | CL2015002530A1 (me) |
| CR (1) | CR20150416A (me) |
| CY (1) | CY1119199T1 (me) |
| DK (1) | DK2970221T3 (me) |
| EA (1) | EA027012B1 (me) |
| ES (1) | ES2639793T3 (me) |
| GT (1) | GT201500263A (me) |
| HR (1) | HRP20171151T1 (me) |
| HU (1) | HUE033482T2 (me) |
| IL (1) | IL240962B (me) |
| JO (1) | JO3383B1 (me) |
| LT (1) | LT2970221T (me) |
| ME (1) | ME02805B (me) |
| MX (1) | MX363438B (me) |
| MY (1) | MY188145A (me) |
| NZ (1) | NZ710392A (me) |
| PE (1) | PE20151654A1 (me) |
| PH (1) | PH12015502091B1 (me) |
| PL (1) | PL2970221T3 (me) |
| PT (1) | PT2970221T (me) |
| RS (1) | RS56122B1 (me) |
| SG (1) | SG11201507541PA (me) |
| SI (1) | SI2970221T1 (me) |
| TN (1) | TN2015000349A1 (me) |
| TW (1) | TWI622396B (me) |
| UA (1) | UA116125C2 (me) |
| WO (1) | WO2014143601A1 (me) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2906555T1 (sl) * | 2012-10-15 | 2017-02-28 | Pfizer Ireland Pharmaceuticals Operations Support Group | Postopek za pripravo vorikonazola in njegovih analogov |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| ME03780B (me) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
| ES2689526T3 (es) | 2013-03-14 | 2018-11-14 | Janssen Pharmaceutica Nv | Moduladores de P2X7 |
| JO3773B1 (ar) | 2013-03-14 | 2021-01-31 | Janssen Pharmaceutica Nv | معدلات p2x7 |
| AU2014230814B2 (en) | 2013-03-14 | 2017-12-21 | Boehringer Ingelheim International Gmbh | Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| EP3112366B1 (en) | 2013-03-14 | 2018-02-28 | Janssen Pharmaceutica NV | P2x7 modulators |
| EA201690458A1 (ru) | 2013-08-23 | 2016-07-29 | Инсайт Корпорейшн | Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| KR102510588B1 (ko) | 2014-09-12 | 2023-03-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 카텝신 c의 스피로사이클릭 억제제 |
| EA201790600A1 (ru) | 2014-09-12 | 2017-07-31 | Янссен Фармацевтика Нв | Модулирующие p2x7 n-ацил-триазолопиразины |
| WO2016039977A1 (en) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulators |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| ES2845048T3 (es) * | 2016-09-22 | 2021-07-23 | Cancer Research Tech Ltd | Preparación y usos de derivados de pirimidinona |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| CN108383771A (zh) * | 2018-01-08 | 2018-08-10 | 华东师范大学 | 手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用 |
| GB201807147D0 (en) | 2018-05-01 | 2018-06-13 | Oncologica Uk Ltd | Therapeutic combination |
| NL2021185B1 (en) | 2018-06-26 | 2020-01-06 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Combination Therapy and Use Thereof for Treating Cancer |
| MA53722A (fr) | 2018-09-28 | 2022-03-30 | Janssen Pharmaceutica Nv | Modulateurs de la monoacylglycérol lipase |
| WO2020065613A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| WO2020212434A1 (en) * | 2019-04-16 | 2020-10-22 | Janssen Pharmaceutica Nv | Fused isoindolin-1-one derivatives useful as grk2 inhibitors |
| CN114555596B (zh) | 2019-09-30 | 2025-02-25 | 詹森药业有限公司 | 放射性标记的mgl pet配体 |
| US11891387B2 (en) | 2020-03-26 | 2024-02-06 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400970D0 (sv) * | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| US7576082B2 (en) * | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| ATE545416T1 (de) * | 2006-10-12 | 2012-03-15 | Xenon Pharmaceuticals Inc | Verwendung von spiro-oxindol-verbindungen als therapeutika |
| SG182187A1 (en) * | 2007-06-08 | 2012-07-30 | Abbott Gmbh & Co Kg | 5-heteroaryl substituted indazoles as kinase inhibitors |
| US8648069B2 (en) * | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
-
2014
- 2014-03-04 JO JOP/2014/0067A patent/JO3383B1/ar active
- 2014-03-05 TW TW103107546A patent/TWI622396B/zh active
- 2014-03-07 CN CN201480011202.4A patent/CN105008351B/zh active Active
- 2014-03-07 DK DK14712966.2T patent/DK2970221T3/en active
- 2014-03-07 UA UAA201508675A patent/UA116125C2/uk unknown
- 2014-03-07 RS RS20170791A patent/RS56122B1/sr unknown
- 2014-03-07 AP AP2015008734A patent/AP2015008734A0/xx unknown
- 2014-03-07 US US14/200,141 patent/US9156824B2/en active Active
- 2014-03-07 PE PE2015001925A patent/PE20151654A1/es active IP Right Grant
- 2014-03-07 PT PT147129662T patent/PT2970221T/pt unknown
- 2014-03-07 JP JP2016500764A patent/JP6064079B2/ja active Active
- 2014-03-07 ES ES14712966.2T patent/ES2639793T3/es active Active
- 2014-03-07 SG SG11201507541PA patent/SG11201507541PA/en unknown
- 2014-03-07 PL PL14712966T patent/PL2970221T3/pl unknown
- 2014-03-07 BR BR112015020466-0A patent/BR112015020466B1/pt active IP Right Grant
- 2014-03-07 SI SI201430280T patent/SI2970221T1/sl unknown
- 2014-03-07 MX MX2015012583A patent/MX363438B/es unknown
- 2014-03-07 ME MEP-2017-173A patent/ME02805B/me unknown
- 2014-03-07 KR KR1020157024644A patent/KR101718645B1/ko active Active
- 2014-03-07 AU AU2014228374A patent/AU2014228374B2/en active Active
- 2014-03-07 CA CA2900773A patent/CA2900773C/en active Active
- 2014-03-07 EA EA201591509A patent/EA027012B1/ru not_active IP Right Cessation
- 2014-03-07 WO PCT/US2014/021466 patent/WO2014143601A1/en not_active Ceased
- 2014-03-07 HU HUE14712966A patent/HUE033482T2/en unknown
- 2014-03-07 EP EP14712966.2A patent/EP2970221B1/en active Active
- 2014-03-07 MY MYPI2015703062A patent/MY188145A/en unknown
- 2014-03-07 LT LTEP14712966.2T patent/LT2970221T/lt unknown
- 2014-03-07 HR HRP20171151TT patent/HRP20171151T1/hr unknown
- 2014-03-07 NZ NZ710392A patent/NZ710392A/en unknown
-
2015
- 2015-08-12 TN TN2015000349A patent/TN2015000349A1/en unknown
- 2015-08-14 CR CR20150416A patent/CR20150416A/es unknown
- 2015-08-31 IL IL240962A patent/IL240962B/en active IP Right Grant
- 2015-09-09 CL CL2015002530A patent/CL2015002530A1/es unknown
- 2015-09-09 GT GT201500263A patent/GT201500263A/es unknown
- 2015-09-14 PH PH12015502091A patent/PH12015502091B1/en unknown
-
2017
- 2017-08-10 CY CY20171100861T patent/CY1119199T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20171151T1 (hr) | Inhibitori cdc7 | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| JP2018024682A5 (me) | ||
| JP2015078230A5 (me) | ||
| RU2016146119A (ru) | Новый кристалл тетрациклического соединения | |
| HRP20220258T1 (hr) | Sastavi 1,2,4-oksadiazola i tiadiazola kao imunomodulatora | |
| JP2014221779A5 (me) | ||
| CY1118839T1 (el) | Επικαλυμμενη φαρμακευτικη συνθεση που περιεχει ρεγοραφενιμπη | |
| SG11202010316XA (en) | Perforated capsule hook for stable high speed retract | |
| MD20140073A2 (en) | New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them | |
| JP2017514910A5 (me) | ||
| EA201691136A1 (ru) | Производное на основе 1,2-нафтохинона и способ его получения | |
| PL2964622T3 (pl) | Nowa sól abeksynostatu, powiązana forma krystaliczna, sposób ich otrzymywania i zawierające je kompozycje farmaceutyczne | |
| EA201490578A1 (ru) | Полиморфная форма питавастатина кальция | |
| JP2017535510A5 (me) | ||
| HRP20220358T1 (hr) | Nove soli nilotiniba i njihovi polimorfi | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| JP2017505336A5 (me) | ||
| JP2015506941A5 (me) | ||
| EA201201668A1 (ru) | Δ-кристаллическая форма аргининовой соли периндоприла, способ ее получения и содержащие ее фармацевтические композиции | |
| WO2015002755A3 (en) | Compounds for the treatment of malaria | |
| HRP20161135T1 (hr) | Oblici u krutom stanju n-((s)-2,3-dihidroksi-propil)-3-(2-fluoro-4-jodo-fenilamino)-izonikotinamida | |
| JP2015533801A5 (me) | ||
| IL245260B (en) | Non-aqueous crystalline form of cabazitaxel, process for its preparation and pharmaceutical compositions thereof | |
| HRP20191227T1 (hr) | Derivat 4-(3-pirazolilamino)benzimidazola kao inhibitor jak1, namijenjen liječenju raka |